Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation

Proceedings of the American Thoracic Society

Volumn 3, Issue 7, 2006, Pages 641-644

  Rabe, Klaus F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Guidelines

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; DATA ANALYSIS; DECISION MAKING; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; LUNG FUNCTION; NATIONAL HEALTH SERVICE; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; SPIROMETRY; TREATMENT OUTCOME; UNITED KINGDOM;

PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33748772020     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200604-099SS     Document Type: Conference Paper

References (19)

1. World Health Organization. The World Health Report 2004: changing history. Geneva, Switzerland: World Health Organization; 2004.
2. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001;163:1256-1276.
3. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
4. Heffner JE, Ellis R. The guideline approach to chronic obstructive pulmonary disease: how effective? Respir Care 2003;48:1257-1266.
5. Lacasse Y, Ferreira I, Brooks D, Newman T, Goldstein RS. Critical appraisal of clinical practice guidelines targeting chronic obstructive pulmonary disease. Arch Intern Med 2001;161:69-74.
6. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 (1 Suppl):1S-232S.
7. Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003;22:1-2.
8. Lomas J. Diffusion, dissemination, and implementation: who should do what? Ann N Y Acad Sci 1993;703:226-235.
9. Basinski AS. Evaluation of clinical practice guidelines. CMAJ 1995;153:1575-1581.
10. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39(Suppl 2):II46-II54.
11. Barr R, Celli B, Martinez F, Ries A, Rennard S, Reilly J Jr, Sciurba F, Thomashow B, Wise R. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005;118:1415.e9-1415.e17.
12. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006;27:822-832.
13. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-620.
14. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-777.
15. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1395-1399.
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
17. Stoller JK. Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Chest 1997;111:123S-128S.
18. The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004;24:206-210.
19. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C. Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD J Chron Obstr Pulm Dis 2004;1:303-312.